Approval Of GW Pharma's Cannabidiol Epidiolex 'No Longer A Pipe Dream'
Set to be the first FDA-approved cannabidiol-based drug, Epidiolex would treat seizures associated with the rare childhood epilepsy indications Lennox-Gastaut syndrome and Dravet syndrome.
You may also be interested in...
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.